“We are pleased to secure FDA 510(k) clearance for our SCoV-2 Ag Detect Rapid Test, which demonstrates our commitment to support the ongoing management of COVID-19 infection through rapid diagnostics. We look forward to working with the FDA to further expand our portfolio of respiratory diagnostics,” said Estela Raychaudhuri, InBios’ president.
“As we’ve seen over the last several months, COVID infections are on the rise. Through our direct commercial efforts and our valued distribution partners, we will immediately begin our transition to the 510(k) cleared product to the more than 200,000 CLIA waived laboratories in the US,” said Wendy Bagnato, InBios’ senior marketing and sales manager. “We are grateful for the collaboration with FDA and support from our government partners in gaining this approval.”
Support to achieve the FDA clearance for the SCoV-2 Ag Detect Rapid Self-Test comes in part from a $12.7 million contract with the U.S. Army Medical Materiel Development Activity (USAMMDA) Warfighter Protection and Acute Care (WPAC) Program Management Office funded by the Defense Health Agency (DHA) through the CARES Act; and the U.S. Department of Health and Human Services (HHS), Administration for Strategic Preparedness and Response (ASPR), Biomedical Advanced Research and Development Authority (BARDA) under contract W81XWH-16-D-0009/Task Order W81XWH-20-F-0253 (awarded in 2020).
About InBios: Since 1996, InBios has been a leader in the development of diagnostic tests for emerging infectious diseases and biothreats. Products are designed for superior performance, efficiency and value. These include many FDA market authorized and CE marked assays for arboviruses, parasitic infections, biothreats, and more. InBios continues to anticipate and serve the growing global public health demand. Products in the pipeline include next generation platforms for tick-borne and respiratory diseases. For more information, visit www.inbios.com.
No official endorsement of third parties or their products is made or inferred.
The website is mobile-friendly, easy to navigate, and provides detailed information on endodontic procedures and how they improve patients’ oral health. Each service has its own page, making researching a procedure easy and convenient. The website also contains patient forms, instructions prior to and after appointments, payment capabilities as well as financing information.
The multi-location practice makes getting an appointment for an endodontic procedure as easy as possible. The entire team works across all five locations to accommodate patients in pain immediately, eliminating the need to wait before receiving relief for dental discomfort.
Dr. Vivian Graham received her Doctorate of Dental Surgery from Baltimore College of Dental Surgery. She completed multiple residencies, including general practice and endodontic studies. Dr. Graham is a member of the American Association of Endodontists, the American Dental Association, and local organizations. Her peers consecutively voted Dr. Graham as one of NJ’s Top Dentists from 2012 to 2023. She has also received recognition in Benco’s Incisal Edge 40 under 40 doctors in 2018. Dr. Graham was also recognized by TD Bank for Small Business Women’s Month, in 2022, highlighting her practice.
Dr. Joseph Rinaggio received his dental degree from the State University of New York at the Buffalo School of Dental Medicine. He is an active oral pathologist and board-certified endodontist. He has also been an Assistant Professor of Oral and Maxillofacial Pathology at the University of Medicine and Dentistry in New Jersey.
Dr. Tara Mahpour completed her dental degree and an Endodontics Residency at the Rutgers School of Dental Medicine. Her clinical research focused on apicoectomies.
Dr. Rene Shin received her Doctor of Dental Surgery degree and completed an Endodontics Residency at the Columbia University College of Dental Medicine. She has published award-winning research in the field of endodontics.
Dr. Nelson Guanche received his Doctor of Dental Medicine degree from the University of Florida College of Dentistry and undertook an Endodontic Residency at Rutgers School of Dental Medicine.
Dr. David Cifelli received his Doctor of Dental Medicine degree from Rutgers School of Dental Medicine (RSDM) and completed a General Practice Residency at Robert Wood Johnson University Hospital in New Brunswick, NJ. He then returned to RSDM for his specialty training in endodontics, where he earned a Master of Dental Science degree.
“When our patients arrive in our offices, they may be anxious about receiving endodontic care. We do everything we can to help them feel comfortable,” said Dr. Graham. “Our priority is helping our patients overcome dental pain and preserving their natural teeth as often and for as long as possible. We take our responsibility to our patients seriously but with a warm, friendly approach.”
Modern Micro Endodontics uses EdgePRO lasers in all five locations. Laser endodontic equipment cleans and sanitizes the root canal with no patient discomfort, killing bacteria and enabling the treatment of complex anatomy.
Modern Micro Endodontics provides specialty endodontic care, including the following procedures:
Non-surgical endodontics: Root canal therapy and endodontic retreatment
The in-office CBCT scanner also enables dentists to detect jaw infections and monitor teeth needing root canals. The scanner also helps safely plan dental implant surgery.
Ridgeview Family Dental recently renovated its office space, creating a beautiful, comforting environment with many patient amenities. Patients of all ages find the space calming.
The practice cares for most oral health needs under one roof, saving patients time and effort traveling to multiple locations. Whether patients need a pediatric cleaning, a root canal, or a dental implant, the treatment team can help.
Dr. J. Allen Burleson, Dr. R. Wesley Lauderback, and Dr. Trey Lunsford care for every family member, from toddlers to grandparents. They are proud that multi-generational families continue to choose Ridgeview Family Dental for their oral health needs.
Led by owner Dr. Lauderback, Ridgeview Family Dental prides itself on a professional, committed staff. Most employees are long-term team members, providing a unique quality of dental care. The team handles all patient interactions with warmth, friendliness, and integrity.
“Promoting lifelong oral health is our first priority,” says Dr. Lauderback. “We want to ensure that our patients know how to protect themselves from tooth decay, gum disease, and other dental problems. We can also restore smiles and improve their appearance.”
Services Offered
General Dentistry: The practice treats patients of all ages, from children to adults.
Restorative Dentistry (crowns, bridges, implants, and dentures)
Cosmetic Dentistry (including veneers, teeth whitening, bonding, and microabrasion)
Dental Implants
Same-Day Crowns
Teeth Whitening
Snoring Therapy
Dental Emergencies (prompt appointments during office hours and after-hours availability)
About Ridgeview Family Dental
Ridgeview Family Dental provides state-of-the-art care in a family-friendly environment. The practice may be reached online at https://www.ridgeviewfd.com. Its address is 222 Headtown Rd, Jonesborough, TN, 37659. Its telephone number is (423) 753-9191.
Leslie A. Chambers, President & CEO of APDA comments, “At APDA, we believe in the power of progress and the hope it brings to the Parkinson’s community. Our mission is deeply rooted in our tagline, ‘Strength in optimism. Hope in progress.’ By providing essential seed funding, we empower researchers to explore innovative ideas and gather critical pilot data. This early support often acts as a catalyst, enabling them to secure larger grants from prestigious institutions like the National Institutes of Health.” Chambers continues, “We are immensely proud to play a pivotal role in advancing these groundbreaking projects that might otherwise never take flight, and in doing so, we continue to bring hope to everyone impacted by Parkinson’s disease.”
Grants for the 2024-2025 funding year have been awarded in the form of five Post-Doctoral Fellowships, eight Research Grants, three Diversity in Parkinson’s Disease Research Grants, nine APDA Centers for Advanced Research, and one George C. Cotzias Memorial Fellowship, APDA’s most prestigious award.
For the fifth year in a row, APDA is awarding a specialized grant to researchers focused on diverse and under-represented communities. APDA created the first-of-its-kind Diversity in Parkinson’s Disease Research Grant in 2019 to encourage and support researchers who are committed to diversity-focused research so we can learn more about how the disease affects different populations and better serve people with PD from all communities.
All APDA grants are awarded through a competitive application process and reviewed by APDA’s esteemed Scientific Advisory Board (SAB), which is comprised of scientists with a wide range of backgrounds and expertise in all areas relevant to PD research. The SAB meets annually to diligently and methodically review all grant proposals and determine the most promising and innovative research to fund.
“As always, our Scientific Advisory Board reviewed many excellent applications and had to make tough choices about whom to fund,” states Rebecca Gilbert, MD, PhD and Chief Mission Officer at APDA. “We have an incredible responsibility to the Parkinson’s community to choose the research that shows the most promise for real progress, as well as a responsibility to our donors to make sure every dollar counts in the search for answers. It is a challenging process, approached with the utmost care and diligence, and I am proud of both the quality and quantity of promising projects and researchers that we are able to fund this year.”
The George C. Cotzias Fellowship is APDA’s most prestigious grant and is awarded to a young physician-scientist with exceptional promise who is establishing a career in research, teaching, and clinical services relevant to Parkinson’s. The award spans three years and is designed to fund a long-range project focused on PD. This year’s awardee is:
William Zeiger, MD, PhD – The Regents of the University of California, Los Angeles | Neuronal microcircuit mechanisms of posterior cortical dysfunction and cognitive impairment in a mouse model of Parkinson’s disease
APDA Diversity in Parkinson’s Disease Research Grants are one-year grants to study the health inequities and/or differences among under-studied PD communities, across the spectrum of ethnicity, ancestry, geography, socioeconomic conditions, and gender. This year’s awardees are:
Ignacio Mata, PhD – Cleveland Clinic Foundation | Machine-learning model for predicting levodopa-induced dyskinesias in a large cohort of Latinos with Parkinson’s disease
Melissa Nirenberg, MD, PhD – Bronx Veterans Medical Research Foundation, Inc. | Parkinson’s disease phenotype in Black and Hispanic veterans
Danielle Shpiner, MD – Miller School of Medicine of the University of Miami | Improving access to advance care planning for Hispanic people with Parkinson’s disease
Post-Doctoral Fellowships are awarded to support post-doctoral scientists who recently completed their PhD work and whose research holds promise to provide new insights into the pathophysiology, etiology, and treatment of PD. This year’s awardees are:
Andrew Monaghan, PhD – Emory University | Electrophysiological characterization of neural circuit pathophysiology underlying freezing of gait
Yuxiao Ning, PhD – The Regents of the University of Minnesota, Twin Cities | Multiregional neural population dynamics in Parkinson’s disease and during directional deep brain stimulation
Brianne Rogers, PhD – HudsonAlpha Institute for Biotechnology | Mechanisms of SNCA regulation
Carlos Soto-Faguás, PhD – Oregon Health & Science University (OHSU) | The effects of the ApoE Christchurch variant on Lewy body pathology development and spreading
Donghe Yang, PhD – Memorial Sloan Kettering Cancer Center (MSK) | Characterizing and modeling the development of human A9 midbrain dopaminergic neurons with pluripotent stem cells
Research Grants are awarded to investigators performing innovative PD research at major academic institutions across the United States. This year’s awardees are:
Patricia Aguilar Calvo, PhD – University of Alabama at Birmingham | Heparan-sulfate mediated mechanisms of a-synuclein propagation in Parkinson’s disease
Athanasios Alexandris, MD – Johns Hopkins University School of Medicine | Investigating the role of a-synucleinopathy in axonal protein homeostasis and viability
Saar Anis, MD – Cleveland Clinic Foundation | Deep brain stimulation neural recordings analysis of varied stimulation parameters during sleep in Parkinson’s disease (The DREAMS-PD Study)
Helen Hwang, MD, PhD – Washington University School of Medicine | Identification and characterization of compounds for fibril growth inhibition
Francesca Magrinelli, MD, PhD – University College London Institute of Neurology | Dissecting PSMF1 as a new gene for early-onset Parkinson’s disease/parkinsonism
Franchino Porciuncula, PT, DScPT, EdD – Trustees of Boston University, CRC | Does rhythmic auditory stimulus reduce the cognitive demands of moderate intensity walking in Parkinson’s disease?
Emily Rocha, PhD – University of Pittsburgh | Lysosomal dysfunction in Parkinson’s disease
Mariangela Scarduzio, PhD – University of Alabama at Birmingham | Striatal acetylcholine dynamics in L-DOPA-induced dyskinesia
In addition, continued funding was granted for eight APDA Centers for Advanced Research, and a new APDA Center for Advanced Research was funded (Yale School of Medicine), to support various programs including research trainees, clinical fellowship programs, early-stage discovery programs and later-stage clinical translation. These Centers facilitate research that is at the forefront of investigation into the causes, treatments and ultimately the cure for PD. The current APDA Centers for Advanced Research are:
Boston University School of Medicine, Boston, MA
Emory University School of Medicine, Atlanta, GA
Mayo Clinic, Jacksonville, FL
Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ
The Brigham and Women’s Hospital, Boston, MA
University of Alabama at Birmingham School of Medicine, Birmingham, AL
University of Pittsburgh Medical Center, Pittsburgh, PA
Washington University School of Medicine, St. Louis, MO
Yale School of Medicine, New Haven, CT
“We are confident that the research we are funding will make a significant impact in the fight against Parkinson’s disease,” says Chambers. “This vital work is made possible by the support of our generous APDA donors.”
Researchers and physicians who are interested in applying for APDA funding can visit http://www.apdaparkinson.org/research for information about 2025-2026 funding opportunities. Letters of Intent for the 2025-2026 grant cycle can be submitted beginning October 2024 with a deadline of December 16, 2024.
Those who want to support APDA’s critical research efforts with a donation can do so by visiting http://www.apdaparkinson.org/donate or by mailing a check payable to the American Parkinson Disease Association to: APDA, PO Box 61420, Staten Island, NY 10036.
About the American Parkinson Disease Association: The American Parkinson Disease Association (APDA) is a nationwide grassroots network dedicated to fighting Parkinson’s disease (PD) and works tirelessly to help the approximately one million people with PD in the United States live life to the fullest in the face of this chronic, neurological disorder. Founded in 1961, APDA has raised and invested more than $282 million to provide outstanding patient services and educational programs, elevate public awareness about the disease, and support research designed to unlock the mysteries of PD and ultimately put an end to this disease. To join in the fight against PD and to learn more about the support APDA provides nationally through a network of Chapters and Information & Referral (I&R) Centers, as well as a national Research Program and Centers for Advanced Research, please visit http://www.apdaparkinson.org.
This week at the Kind & Jugend International baby + toddler show, Kids2’s booth (10 Plain: 2 Aisle: FN: 048) will proudly showcase its breadth of product innovation and global solutions, across its marquee brands. With a focus on the company’s Big 7 bets designed to make a meaningful difference in the lives of families, attendees will see how Kids2 brands are with families every step of the way from birth to toddlerhood, offering a comprehensive, one-stop-shop of solutions for parents and caregivers:
Learning Solutions with Baby Einstein, the brand that helps inspire curiosity in both baby and parent through its products based on “The Einstein Way” learning philosophy, backed by science and built from the best childhood development research.
Healthy Sleep through its innovative approach with Ingenuity—keeping baby calm and comforted with swaddles, bassinets and soothers helping both parent and baby sleep easy with a safe and comfortable environment.
Potty train with the essentials supported by resident experts like Allison Jandu.
Stay secure with functioning stylish Ingenuity security gates that not just fit any budget and match decor style, but easy-to-install.
Quick, safe and easy on-the-go with Quick Close Stroller and a breadth of “pop-up” portable essential products, including the Pop ‘N Sit portable booster seat (more than 2 million sold).
Superior style with our Chic Boutique Collection, offering comfort, connectivity, safety and peace of mind at accessible price points.
Amazing licensing partnerships with Winne the Pooh. Everyone’s favorite bear is coming out of the Hundred Acre Wood and into stores with a new contemporary collection that is sweeter than honey, including a door jumper consumers can’t get enough of!
Whether it’s soothing a newborn, supporting a baby’s first steps, or making mealtime more enjoyable, Kids2 supports parent and baby with a product lineup that reflects a deep understanding of what families truly value and need.
Kids2’s participation at K&J underscores its role as a leader in the market, bringing innovative, creative, and functional products to new regions and communities.
Panacea Healthcare Solutions is committed to fostering knowledge-sharing and collaboration in the healthcare industry. The NAHRI RIS Symposium provides a unique platform to explore best-practice strategies for enhancing the CDM’s value and clarity. By utilizing the right resources and fostering collaboration among CDM professionals, financial leadership, and external experts, organizations can optimize revenue integrity and ensure a solid foundation for financial success.
Attendees of the symposium will have the opportunity to engage with Panacea’s experts to gain valuable insights into enhancing revenue integrity and promoting effective charge management strategies. Panacea will be showcasing ChargeAssist®, its enterprise solution for charge management designed to support healthcare organizations in achieving optimal revenue integrity.
“Panacea Healthcare Solutions is thrilled to be a part of this symposium, contributing to the industry’s growth and knowledge exchange,” added Meadows. “We look forward to connecting with attendees and sharing our expertise on how to leverage ChargeAssist for improved charge management and revenue integrity.”
Panacea invites all attendees to stop by booth #19 to meet their experienced Revenue Integrity team and learn more about how their solutions, including ChargeAssist, can support your organization’s revenue integrity and charge management strategies.
For more information about ChargeAssist and Panacea Healthcare Solutions and their participation in the NAHRI RIS Symposium, please visit https://www.panaceainc.com/chargeassist/.
Biorelate specialises in advanced data science methods for drug discovery to deliver robust, evidence-based intelligence to those making critical decisions about the next drugs to take forward. The actionable insights it distils, from across diverse ‘dark’ (previously unsearchable) knowledge assets and existing texts, ensure that investment is concentrated on the targets most likely to succeed in drug development – with a positive impact for patients, while delivering financially for the drug developer and its backers.
Dr Sidders, who has followed Biorelate closely since the company’s foundation in 2014, believes the company is at an important inflection point thanks to its proven technology and a significant opportunity to grow and scale. That’s as drug developers look to next-generation data science to transform their early research, and improve new drug candidates’ probability of success.
Of the opportunity Biorelate addresses, Dr Sidders said: “The pharmaceutical industry is rapidly adopting data science-driven approaches using artificial intelligence. This has meant a shift away from the traditional pharma R&D model (very low throughput, with heavy reliance on academic literature to determine new targets), towards an Artificial Intelligence (AI)-first approach.
“The risk with this approach is that researchers do not really understand the causality of their findings, which is critical if you want to develop a successful drug. Biorelate fills that gap by drawing on a wealth of data to develop causal models and explaining – mechanistically and in the appropriate context – what the next opportunities are and why. Crucially, Biorelate’s technology platform has causality built in – something that’s lacking in other AI approaches to drug discovery. It has proven adept at finding new targets, and has promise in other areas of the pipeline too, from biomarker discovery and patient stratification to the identification of promising drug combinations. This is a really exciting time for Biorelate, and for data science in drug discovery more broadly.”
Daniel Jamieson, Biorelate’s CEO, said: “This prestigious appointment is an important endorsement of the great work we are doing, and we are delighted to welcome Ben on board. His scientific direction will give Biorelate an even deeper footing within modern drug discovery and development.
“At AstraZeneca, Ben’s team was responsible for delivering data-driven, actionable insights to all parts of the company’s oncology portfolio, including advancing the understanding of disease. His years at Pfizer, and his extensive experience of all facets of drug discovery across major pharma, add richly to his understanding of what the industry needs now to transform R&D performance – insights and expertise we can now extend to our diverse client base.”
Dr Sidders’ personal fields of interest include immuno-oncology, network biology and the role of bioinformatics within drug discovery. He has a PhD in Molecular Biology & Bioinformatics from the University of London where his thesis focused on the development of predictive markers for the diagnosis of asymptomatic Tuberculosis. Ben holds patents for two clinical diagnostics and has authored over 30 scientific publications.
About Biorelate
Biorelate is a world leader in leveraging advanced data science methods to extract critical knowledge from vast amounts of pharmaceutical data and literature, significantly enhancing the discovery of novel biopharmaceuticals. Biorelate offers multiple product lines powered by its proprietary platform, Galactic AI™.
Galactic AI™ employs sophisticated natural language processing (NLP) and artificial intelligence (AI) to uncover hidden cause- and-effect relationships. This innovative platform provides unprecedented insights into disease pathways, enabling more precise and effective drug discovery. As the incredible progress of scientific researchers continues to compound the huge volume of growing and evolving biomedical data, Biorelate’s mission to curate knowledge to advance the world’s most promising biomedical innovations has never been so important.
The Wall Street Technology Association (WSTA®), a not-for-profit organization that provides financial technology and business professionals a forum to learn from and connect with each other, will host a virtual educational event on “Mastering Digital Experiences” on September 19, 2024.
NEW YORK, Sept. 5, 2024 /PRNewswire-PRWeb/ — The Wall Street Technology Association (WSTA®), a not-for-profit organization that provides financial technology and business professionals a forum to learn from and connect with each other, will host a virtual educational event on “Mastering Digital Experiences” on September 19, 2024.
Speakers at this event include Keynote and Panel Moderator: Joseph Kennedy, Partner, PwC; Premier Sponsor: Riverbed Technology and Speaking Sponsor: Verizon Business. Financial Services firms will also be on the panel. For more information, please visit: https://www.wsta.org/event/digital-experience-dcx-dex/
Event Description This event explores the DCX and DEX strategies bringing in the biggest wins for financial services firms. Join us for an insightful session exploring the limitless potential of DCX and DEX! We’ll dive into topics including: Personalization & Customization
How can financial services firms leverage data analytics and AI to create highly personalized experiences?
How can they anticipate and meet the needs of both customers and employees?
Omni-channel Engagement & Compliance
How can financial services firms create a seamless experience for customers across multiple digital channels such as mobile apps, websites, social media, and chatbots?
What guardrails should be in place to balance the need for seamless experiences with compliance and privacy standards?
Uses for AI
Can we finally build chatbots that customers and employees find helpful and want to use?
How can we gauge employee and customer sentiment without having to ask for feedback directly?
Is a custom GPT right for your organization?
We know AI can automate repetitive tasks for us. How can it assist with choosing the best tasks to automate?
Panel Discussion: Crafting a World-Class DCX/DEX Program Join our financial services thought leaders and technology experts as we discuss how to put together a world-class program for DCX and DEX. We’ll talk about emerging technologies, operational excellence, and the most critical KPIs for measuring success. And we’ll share the pitfalls and challenges. This lively and engaging dialogue will spark ideas and insights for all participants.
About the Wall Street Technology Association (WSTA) The WSTA facilitates virtual and in-person educational and networking events where members meet and exchange ideas and best practices that assist them in effectively capitalizing on technology advances in areas such as Cybersecurity, Analytics, Artificial Intelligence (AI), Mobility, Wireless, Machine Learning (ML), Data, Cloud, Blockchain, Digital, Architecture, etc. and dealing with financial industry business challenges. Founded in 1967, the WSTA is a not-for-profit association with a long history of evolving to meet the needs of its members.
The WSTA hosts seminars, roundtables, panel discussions, and social events. These events offer many opportunities to learn about leading technologies, as well as network and share information with industry colleagues. The WSTA’s educational newsletter, TechTrends, provides additional content and information about the WSTA and industry-related activities. The website is a dynamic resource providing access to additional resources including webinars, white papers, videos, and information about other industry events.
A new mobile imaging pad outside the hospital also now supports rotating MRI and PET CT capabilities, substantially enhancing patient access to these critical services in the community. The mobile MRI truck operates three days a week, adding 40 MRI appointment slots weekly, while the PET CT truck is available every Wednesday and on the first, third, and fifth Thursdays of each month.
AHN and Highmark Health’s investment in the new imaging center reflects a growing demand for imaging services in the Allegheny Valley region.
“These upgrades to our imaging capabilities at AVH ensure that patients have access to the most accurate and comprehensive diagnostic services available close to home,” said Mark Rubino, MD, president of Allegheny Valley Hospital. “The new mobile imaging capabilities, in particular, allow us to provide more timely and convenient care to our patients, reducing wait times and improving overall patient experiences and outcomes. It’s another great example of AHN bringing our Living Health model to life in this community.”
The PET CT service is especially crucial for cancer patients, enabling more precise staging and treatment planning.
This expansion also aligns with updated national guidelines recommending that women begin breast cancer screenings at age 40, instead of 50. Additionally, the U.S. Food and Drug Administration now mandates that mammography facilities inform patients about breast density to better assess their risk profile for breast cancer.
“Early detection and treatment of breast cancer are essential for helping our patients live their best and healthiest lives, and we are thrilled to offer these enhanced imaging services to the community that Allegheny Valley serves,” said Bethany Casagranda, DO, chair of the AHN Imaging Institute. “Our cancer patients can now receive their PET scans right here at AVH, eliminating the need to travel to other facilities. This not only provides convenience but also ensures continuity of care.”
The department’s physical space has been significantly upgraded to enhance patient comfort and convenience, including newly renovated check-in and check-out areas, expanded waiting rooms for gowned patients, and ADA-compliant dressing rooms.
“We’ve refreshed and modernized our facilities to create a more welcoming and accessible environment for our patients,” Rubino said. “These improvements reflect our commitment to delivering the highest quality of care in a comfortable and patient-friendly setting.”
The newly renovated radiology department at AVH is the latest in a series of substantial investments by AHN and Highmark Health in the network’s Imaging Institute facilities across the greater western Pennsylvania region in recent years. The Network opened its new imaging center at the AHN Bethel Park Health + Wellness Pavilion late last year and will soon cut the ribbon to new imaging facilities at both Jefferson Hospital and Allegheny General Hospital.
Patients can self-schedule an appointment by visiting http://www.ahn.org or calling 412-DOCTORS. Established AHN patients may also schedule an appointment via MyChart.
Dr. Melissa Hunter-Ensor, co-chair of the Patents and Innovation Strategies Group of global law firm Greenberg Traurig, LLP, was named a 2024 “Go To Healthcare/Life Sciences Lawyer” by Massachusetts Lawyers Weekly.
BOSTON, Sept. 4, 2024 /PRNewswire-PRWeb/ — Dr. Melissa Hunter-Ensor, co-chair of the Patents and Innovation Strategies Group of global law firm Greenberg Traurig, LLP, was named a 2024 “Go To Healthcare/Life Sciences Lawyer” by Massachusetts Lawyers Weekly. She and her fellow honorees are featured in the publication’s Aug. 19 edition. Hunter-Ensor also received this recognition in 2022.
“Go To” Lawyers are nominated by their peers and chosen by a panel from Massachusetts Lawyers Weekly. Honorees are selected for demonstrating in-depth knowledge in their field and deep experience with a record of success, according to the publication.
“Melissa’s exceptional experience and dedication have bolstered the firm’s patent practice and also advanced the fields of life sciences and health care. This recognition reflects her capabilities and leadership, and reinforces Greenberg Traurig’s commitment to providing top-tier life sciences legal counsel. We congratulate Melissa on this well-deserved honor,” Boston office Co-Managing Shareholders David J. Dykeman and Terence P. McCourt said in a joint statement.
Hunter-Ensor focuses her practice on the IP and commercial needs of clients in the life sciences industry, encompassing pharmaceutical, biotechnology, chemical, agricultural, diagnostics, and medical device companies. She has experience representing clients throughout the business cycle, from startups and universities to global pharmaceutical companies, patent portfolio management, and strategic alliances, as well as litigation and pre-litigation strategy. Hunter-Ensor also assists venture capital firms and other investors in assessing the IP risks of target investments and conducts IP patent and licensing due diligence in connection with complex life science technology transactions.
About Greenberg Traurig’s Boston Office: Celebrating 25 years of legal excellence, Greenberg Traurig’s Boston office is home to more than 90 attorneys practicing in the areas of banking and finance, corporate, emerging technology, energy, environmental, gaming, governmental affairs, intellectual property, labor and employment, life sciences and medical technology, litigation, public finance, real estate, restructuring and bankruptcy, tax, and white collar defense and investigations. An important contributor to the firm’s international platform, the Boston office includes a team of nationally recognized attorneys with both public and private sector experience. Working collaboratively with the firm’s global network, the Boston team collectively offers clients decades of experience advising on complex legal matters and providing hands-on knowledge of the local business community.
About Greenberg Traurig: Greenberg Traurig, LLP has more than 2750 attorneys in 47 locations in the United States, Europe and the Middle East, Latin America, and Asia. The firm is a 2022 BTI “Highly Recommended Law Firm” for superior client service and is consistently among the top firms on the Am Law Global 100 and NLJ 500. Greenberg Traurig is Mansfield Rule 6.0 Certified Plus by The Diversity Lab. The firm is recognized for powering its U.S. offices with 100% renewable energy as certified by the Center for Resource Solutions Green-e® Energy program and is a member of the U.S. EPA’s Green Power Partnership Program. The firm is known for its philanthropic giving, innovation, diversity, and pro bono. Web: http://www.gtlaw.com.
Media Contact
Lisa Murray, Greenberg Traurig, LLP, 978.750.0333, [email protected], gtlaw.com
